Peginterferon alfa-2a is used alone or with other medicines to treat chronic hepatitis C in adults and children at least 5 years old. Peginterferon alfa-2a is also used to treat chronic hepatitis B when the virus begins to damage the liver in adults and children at least 3 years old. Peginterferon alfa-2a may also be used for purposes not listed in this medication guide. When taking peginterferon alfa-2a with other medicine : To make sure all medicines are safe for you, tell your doctor about all your medical conditions, and if you are pregnant or breastfeeding.
Peginterferon Alfa-2a Injection
PEGINTERFERON ALFA | Drug | BNF content published by NICE
Proteinuria rare , not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.
Peginterferon Alfa-2b Injection (Sylatron)
If you take a weekly injection of interferon, you owe thanks to a chemist. This is because without the chemistry of pegylation you would need to inject interferon up to three times a week. In short, pegylation makes taking your medicine easier and actually makes it work better.
Background: Chronic hepatitis C virus HCV infection is prevalent in dialysis patients, and standard interferon monotherapy is the current standard of care for such patients. Aim: To investigate whether pegylated interferon has a better therapeutic efficacy and safety profile than standard interferon in dialysis patients with chronic hepatitis C. Methods: 50 such patients were randomly assigned to receive either pegylated interferon alpha-2a microg subcutaneously once per week or standard interferon alpha-2a 3 million units subcutaneously thrice per week for 24 weeks. The primary efficacy and safety end points were sustained virological response SVR by intention-to-treat analysis and treatment-related withdrawal rate during the study. Conclusions: Pegylated interferon alpha-2a once weekly provides more effective and safer therapy than standard interferon alpha-2a thrice weekly for treatment-naive dialysis patients with chronic hepatitis C.